Relapse remains the major cause of treatment failure in children with highrisk acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem-cell transplantation (allo-SCT). Prognosis is considered dismal but data on risk factors and outcome are lacking from prospective studies. We analysed 242 children with recurrence of ALL after first allo-SCT enrolled in the Berlin-Frankfurt-Munster (BFM) ALL-SCT-BFM 2003 and ALL-SCT-BFM international 2007 studies. Median time from allo-SCT to relapse was 7Á7 months; median follow-up from relapse after allo-SCT until last follow-up was 3Á4 years. The 3-year event-free survival (EFS) was 15% and overall survival (OS) was 20%. The main cause of death was disease progression or relapse (86Á5%). The majority of children (48%) received salvage therapy without second allo-SCT, 26% of the children underwent a second allo-SCT and 25% received palliative treatment only. In multivariate analyses, age, site of relapse, time to relapse and type of salvage therapy were identified as significant prognostic factors for OS and EFS, whereas factors associated with first SCT were not statistically significant. Combined approaches incorporating novel immunotherapeutic treatment options and second allo-SCT hold promise to improve outcome in children with post allo-SCT relapse.
Allogeneic haematopoietic stem-cell transplantation (allo-SCT) has become the standard of care in children with very high-risk acute lymphoblastic leukaemia (ALL) (Eckert et al, 2001 (Eckert et al, , 2013 Woolfrey et al, 2002; Borgmann et al, 2003; Eapen et al, 2006 ). According to current data survival rates for children undergoing allo-SCT in first or second complete remission from either human leucocyte antigen (HLA)-identical sibling or HLA-matched unrelated donors approach 70-75% . In these contemporary cohorts, non-relapse mortality was substantially reduced via optimized donor selection and supportive care strategies. Despite aggressive conditioning regimens leukaemic relapses are the major cause of treatment failure with a cumulative incidence of 20-25% and the risk of relapse primarily depending on disease and remission status before allo-SCT. (Schrauder et al, 2006; Peters et al, 2015) Based on the dismal outcome of these patients, standard-of-care treatment protocols for the clinical scenario of relapse after allo-SCT are lacking. Thus, treatment is highly patient-individualized, comprising various approaches ranging from palliative care to cessation of immunosuppression to enhance the graft-versus-leukaemia (GvL) effect, donor lymphocyte infusions (DLI), salvage chemotherapy, second allo-SCT or experimental therapies (Bader et al, 1999 (Bader et al, , 2004 Willasch et al, 2016; Roux et al, 2017) . Innovative leukaemia-specific immunotherapies, such as CD19-or CD22-directed monoclonal antibodies and immuno-conjugates as well as CD19-specific chimeric antigen receptor (CAR) T-cells, have become available more recently. These are probably also most effective when used in a minimal residual disease (MRD) setting rather than in overt relapse (Topp et al, 2012; Grupp et al, 2013; Schlegel et al, 2014; Bader et al, 2015) . To date, second allo-SCT represents the most common treatment option providing a chance for cure in these children. However, this approach still requires achieving a complete morphological remission, preferably with a negative or low MRD level, to provide a reasonable chance for clinical benefit. As the recurring leukaemic blasts escaped both conventional chemotherapy and immunological attacks during first allo-SCT, the identification of novel therapeutic targets based on next-generationsequencing analysis represents one innovative approach urgently warranted for proper drug selection in these highly pre-treated children (Chen et al, 2015; Fischer et al, 2015; Shalabi et al, 2015) .
Intensive chemotherapy can induce remission in some adult patients who relapse after first allo-SCT, but remission durations are typically short, and most patients die of uncontrolled leukaemia, infectious complications and/or graft-versus-host disease (GvHD) (Michallet et al, 2000; Bosi et al, 2001; Eapen et al, 2004) . Thus far, prognosis is generally considered dismal in children relapsing after allo-SCT but data on outcome and prognostic factors are still scarce and are primarily derived from heterogeneous case series or registry analyses comprising different leukaemia entities and highly variable primary transplant approaches (Kato et al, 2012; Bajwa et al, 2013; Naik et al, 2015; Menon et al, 2016; Roux et al, 2017) .
We therefore analysed the detailed outcome and prognostic factors of a large cohort of paediatric patients relapsing with ALL after allo-SCT homogeneously transplanted within 
Patients and methods

Study design
Outcomes of first relapse after allo-SCT in children with ALL treated according to the prospective multicentre ALL-SCT-BFM 2003 and ALL-SCT-BFM international 2007 trials utilizing identical transplant procedures (Schrauder et al, 2008) were analysed. Allo-SCT, including donor selection, stem-cell source, conditioning regime and GvHD prophylaxis, was performed on the basis of the ALL-SCT-BFM 2003 and international 2007 study recommendations . Data obtained by the ALL SCT trial centre in Vienna, Austria, until June 2016 were included in this analysis. For patients who experienced relapse after allo-SCT, site of relapse, salvage therapy, second SCT and outcome were analysed based on data reported to the trial centre.
For reasons of clarity and comparability, we categorized post-relapse treatment into three therapy groups: palliative treatment (defined as low dose chemotherapy and/or supportive care only), salvage therapy with or without second SCT. Multidrug chemotherapy was defined as therapy comprising of more than 2 different drugs.
The ALL-SCT studies were performed in accordance with the Declaration of Helsinki and Good Clinical Practice and were approved by the local institutional review boards at each participating site. Patients and/or their legal guardians provided written informed consent before enrolment.
Inclusion criteria
Patients who were previously treated according to the ALL-SCT-BFM 2003 and international 2007 study were included into this analysis when an ALL relapse after first allo-SCT was reported. A total of 242 patients fulfilled the eligibility criteria.
Statistics
The overall survival (OS) and the event-free survival (EFS) probabilities were calculated using the Kaplan-Meier method and groups were compared using the log-rank test. For OS, death of any cause was used as an event, and, for EFS, second relapse after allo-SCT and death of any cause was used. Starting point for the analysis was the date of first relapse after allo-SCT. Survivors were censored at the date of last follow-up information. The median follow-up time was estimated using the reverse Kaplan-Meier method. The impact of prognostic factors on EFS and OS was evaluated in a univariate and multivariate manner by using the Cox proportional hazards model. The factors potentially associated with the outcome and hence included into the analysis were: age, immunophenotype and remission status of patient at first allo-SCT, donor type, conditioning regimen, and time and site of first relapse after first SCT. An explorative analysis of the impact of salvage therapy after the first relapse post allo-SCT was performed only for the patients who received salvage therapy with or without second allo-SCT. For the purpose of this analysis, the Cox proportional hazards model was used considering the salvage therapy with second SCT as time depending variable, and adjusted for the other possible risk factors mentioned above. All P-values below 0Á05 were considered significant. The statistical analysis was performed using SAS version 9Á4 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
Our study identified 242 patients who relapsed after first allo-SCT; most children (176 of 234; 75Á2%) presented with B-precursor ALL relapse. Median age at allo-SCT was 8Á7 years (range 0Á5-21Á8). The majority of children (138; 57%) received allo-SCT in second complete remission (CR2). Most children (171 of 236; 72Á5%) received a total-body irradiation (TBI)-containing regimen, the predominant stem-cell source was bone marrow in 148 of 238 (60Á2%) cases, and the most-frequent donor was an HLA-matched unrelated donor (MUD) (138; 57Á0%). The median time from allo-SCT to relapse was 7Á7 months (range 0Á9-86Á1). This was shorter in children undergoing SCT in >CR2 compared to CR2 and first CR [5Á3 months (range 1Á3-46Á3) vs. 8Á1 months (range 0Á9-60Á8) vs. 7Á8 months (range 0Á9-86Á1), respectively, P = 0Á259]. The median time from relapse after allo-SCT until last follow-up evaluation was 3Á4 years (range 0Á01-7Á9). Further patient, disease and transplant characteristics are detailed in Table I .
Outcomes following relapse
The 3-year probability of EFS and OS was 15% and 20%, respectively (Fig 1A) . At last follow-up, 190 (78Á5%) children had died. The main cause of death was disease progression or subsequent relapse (166; 87Á8%). Twenty-two (11Á6%) children died of infectious or treatment-related complications; of these, 16 were following second SCT. One child (0Á8%) died of late effects.
Prognostic factors for outcome after relapse after first allo-SCT No differences in EFS were observed between age groups, disease status at first allo-SCT, stem cell sources and conditioning regimen (TBI yes/no) ( Figure S1A , B, D, E). Patients with mismatched donor transplantation did worse when compared to those with MUD or matched sibling donor transplantations (3-year EFS 8% vs. 16% vs. 17%; P = 0Á018) ( Figure S1C ).
Precursor B-cell immunophenotype was associated with better outcome compared to T-cell or other phenotypes (3-year EFS 18% vs. 6% vs. 0%; P = 0Á029) ( Figure 1B ). Children relapsing very early (<6 months from allo-SCT) did significantly worse than children relapsing after 6 months or after 12 months (3-year EFS. 3% vs. 17% vs. 28%, P < 0Á001) (Fig 1C) . Extramedullary relapse was associated with significantly better EFS than bone marrow only or bone marrow combined with extramedullary relapse (3-year EFS 39% vs. 12% vs. 3%, P < 0Á001) (Fig 1D) .
Salvage therapy
Data on relapse therapy were available for 232 (95Á9%) out of 242 children. The majority of children (173; 74Á6%) received salvage therapy either alone (112; 48Á3%) or in combination with second SCT (61; 26Á3%). Of those 61 children receiving second SCT, 25 (41Á0%) are still alive, whereas 22 (19Á6%) out of 112 patients with salvage therapy but without subsequent SCT are still alive. In 59 (25Á4%) children, only palliative treatment was given, with a median time of survival of 2Á3 months (range 0Á2-19Á8 months).
Multivariate analyses
In multivariate analysis of EFS and OS (including age and remission status of patient at first allo-SCT, immunophenotype, donor type, conditioning regime, and time and site of first relapse after first SCT) short time to relapse, age above 12 years, and site of relapse (bone marrow only and bone marrow combined with extramedullary) were identified as significant adverse prognostic factors. Donor type, remission status at first allo-SCT, immunophenotype, and conditioning regime had no significant influence on outcome (Table II) .
Children who were eligible for a second SCT are subject to selection bias as they represent a subgroup of patients with therapy-sensitive post-HSCT relapse. To try to address the prognostic impact of second allo-SCT in this setting, we performed additional multivariate analysis of OS and EFS for the two treatment groups, salvage therapy with and without second allo-SCT, adjusting for the risk factors mentioned above. Salvage therapy with second allo-SCT emerged as significant positive prognostic factor for OS (HR = 0Á52, P = 0Á015) and EFS (HR = 0Á41, P < 0Á001).
Discussion
We report the detailed outcome of a cohort of 242 children with ALL relapse after first allo-SCT homogenously treated within the prospective multicentre ALL-SCT-BFM 2003/international 2007 trials. Short interval from transplantation to relapse, salvage therapy without second allo-SCT, age >12 years, and relapse occurring either in the bone marrow only or combined with extramedullary relapse emerged as significant negative prognostic factors on OS and EFS in multivariable analyses.
Noteworthy, isolated extramedullary relapse proved to be independently associated with better outcome, which has so far only been demonstrated for relapse after chemotherapy without SCT (Hagedorn et al, 2007; Tallen et al, 2010) . In accordance with previously published case series and registry analysis in adults and children, our data indicate that length of remission after first transplantation is probably the most important outcome predictor for relapse after first allo-SCT (Michallet et al, 2000; Bosi et al, 2001; Eapen et al, 2004; Kato et al, 2012; Bajwa et al, 2013; Naik et al, 2015; Menon et al, 2016; Roux et al, 2017) .
Of note, factors associated with first allo-SCT, such as donor type and conditioning regimen, had no impact on EFS and OS in multivariate analysis. This confirms previously published registry data in children and adults suggesting that prognostic factors in the setting of a first allo-SCT may not persist after post-transplant relapse (Michallet et al, 2000; Bosi et al, 2001; Eapen et al, 2004; Kato et al, 2012; Bajwa et al, 2013; Naik et al, 2015; Menon et al, 2016; Roux et al, 2017) . Notably, T-cell immunophenotype as a risk factor for outcome did not persist in multivariate analysis.
Second transplantation has been shown to successfully sustain remission in 20-35% of patients in several series in adults (Michallet et al, 2000; Bosi et al, 2001; Eapen et al, 2004) and up to 43Á9% in children (Menon et al, 2016; Roux et al, 2017) . Our data show that the 3-year EFS was 33Á6% in children undergoing salvage therapy with second SCT. However, these results are subject to selection bias as only those children attaining sufficient disease control are generally considered eligible for second allo-SCT. To address the time to second allo-SCT as one major component of this selection bias, we performed additional multivariate analyses incorporating second allo-SCT as a time-dependent covariate. We found that second allo-SCT faired significantly better than salvage therapy without second SCT.
When considering therapeutic options for individual patients relapsing after allo-SCT, the risk of treatment-related mortality is a major concern, especially in heavily pre-treated children with early relapse after allo-SCT. Although the majority of patients in our series received multidrug chemotherapy comprising three or more drugs and/or a combination therapy including second allo-SCT, only 11Á6% Fig 1. (A) Probability of EFS and OS; Probability of EFS (pEFS) depending on (B) phenotype, time to relapse after first allogeneic stem cell transplantation (allo-SCT) and (D) site of first relapse after allo-SCT. ALL, acute lymphoblastic leukaemia; BM, bone marrow; EFS, event-free survival; OS, overall survival; pEFS, probability of event-free survival.
of the deaths were therapy-related. Thus, treatment-related morbidity and mortality in the relapse situation appears to be a substantial, but largely manageable problem in this prognostically dismal situation.
Some challenges and caveats to interpreting our data should not go unmentioned. Our data were not sufficient to analyse the impact of cytogenetics/molecular subgroups, response to chemotherapy following post allo-SCT relapse and rates of achievement of complete remission AE MRD with subsequent therapy.
However, the data from our analysis present the detailed outcome of a large cohort of relapsing paediatric patients with ALL after allo-SCT homogeneously transplanted within a prospective clinical trial and highlight the urgent clinical need for innovative strategies based on the overall dismal prognosis. As our data are derived from a homogeneously treated trial cohort, they may serve as a reference for evaluation of novel immunological and cellular therapies currently under clinical investigation in the setting of ALL relapse after allo-SCT, such as blinatumomab, inotuzumab-ozogamicin and CD19-and CD22-directed CAR-T-cells. Moreover, our data indicate that, while time from transplantation to relapse remains the most significant prognostic factor, even patients with ALL relapsing between 6 and 12 months after transplantation may benefit from intensive curative therapeutic approaches, including, but not limited to, second allo-SCT.
In this regard, the aforementioned novel antineoplastic strategies -based on their characteristic side-effect profile which clearly differs from conventional chemotherapy -may prove highly beneficial either for achieving complete remission prior to second allo-SCT or even as definitive curative approaches (Grupp et al, 2013; Maude et al, 2014; Shalabi et al, 2015; von Stackelberg et al, 2016) .
Longer time from transplantation to relapse, extramedullary relapse, older patient age and salvage therapy with second allo-SCT are major prognostic factors in children with ALL relapse after first allo-SCT. However, except for patients with extramedullary relapses, outcome of relapse after allo-SCT was dismal. Combined approaches incorporating novel immunotherapeutic treatment options and second allo-SCT hold promise to improve outcome in children with post allo-SCT relapses.
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